What is the recommended treatment for a female athlete with moderate osteoporosis (Z‑score ≤ –2.0), menstrual irregularities and low body mass index who is not planning pregnancy?

Treatment for Moderate Osteoporosis in Female Athletes

The primary treatment for a female athlete with moderate osteoporosis (Z-score ≤ -2.0), menstrual irregularities, and low BMI who is not planning pregnancy is to increase energy availability by 300-600 kcal/day and reduce exercise intensity, with non-pharmacological interventions prioritized over hormonal therapy. 1

Non-Pharmacological Treatment (First-Line)

The cornerstone of management focuses on correcting the underlying energy deficit:

Energy Availability Restoration

• Increase daily caloric intake by 300-600 kcal/day (1.2-2.4 MJ/day) 2
• Address energy distribution throughout the day and around exercise sessions
• Optimize dietary composition with adequate protein and carbohydrate to restore liver glycogen and facilitate LH pulsatility 2
• Reduce exercise intensity or introduce rest days into the weekly training program 2

Nutritional Supplementation

• Calcium: 1000-1300 mg/day from calcium-rich foods 1
• Vitamin D: Maintain serum levels between 32-50 ng/mL (minimum 600 IU daily, higher doses if deficient) 1

Multidisciplinary Team Approach

• Physician for medical management
• Sports dietitian for nutritional counseling
• Mental health provider if disordered eating or eating disorder is present 1
• Athletic trainer and coach involvement 3

When to Consider Pharmacological Treatment

Pharmacological therapy should only be considered after non-pharmacological management has failed for 18-24 months or in specific high-risk situations 1. The decision depends on multiple factors beyond BMD Z-scores alone:

Criteria for Pharmacological Consideration

• Symptoms of estrogen deficiency (vaginal dryness, dyspareunia) 1
• Continued bone loss despite adequate non-pharmacological therapy 1
• Fracture history, particularly recurrent stress fractures 1
• Rate of bone loss on serial DXA assessments 1
• Nature of athletic activity (high-impact vs. low-impact sports) 1

Pharmacological Options (If Non-Pharmacological Fails)

Estrogen Replacement

If pharmacological therapy is warranted after failed non-pharmacological management:

• Transdermal estrogen with cyclic progesterone is preferred over combined oral contraceptives 1
• Combined oral contraceptives (COCs) are NOT consistently effective for improving BMD in amenorrheic athletes and may further compromise bone health through hepatic first-pass effects on IGF-1 production 1
• COCs create a false sense of security with withdrawal bleeding but do not restore spontaneous menses or address the underlying energy deficit 1

Critical Cautions About Pharmacological Treatment

Bisphosphonates should be used with extreme caution in women of childbearing age due to:

• Very long half-life and concerns about teratogenicity 1
• Association with atypical femur fractures and osteonecrosis of the jaw with long-term use 1
• No published studies in exercising women with Female Athlete Triad 1
• Decision must be made case-by-case considering individual fracture risk 1

Not recommended:

• Testosterone, DHEA, leptin, or rhIGF-1 replacement (lack of evidence in female athletes) 1
• Depot medroxyprogesterone (can cause amenorrhea and adversely affect BMD) 2

Monitoring and Follow-Up

• Serial DXA measurements to assess response to treatment 1
• Monitor for return of spontaneous menses (strongest predictor of bone health improvement) 2
• Weight gain is the strongest predictor of recovery of normal menstrual function 2
• Time frame for menses resumption varies by severity and duration of energy deficiency 2

Key Clinical Pitfalls

The most common mistake is prescribing oral contraceptives as first-line treatment. This masks the underlying problem, provides false reassurance, and may worsen bone health 1, 2. The athlete continues training at high intensity with inadequate energy availability while believing the problem is "treated."

Another critical error is initiating pharmacological therapy without addressing energy availability. No medication will be effective if the fundamental energy deficit persists 1, 2.

The impact loading characteristics of the athlete's sport matter significantly—high-impact sports may partially protect BMD even in amenorrheic athletes, while low-impact sports show the lowest BMD in amenorrheic athletes 4.